Nooruddin Pracha

Dr. Nooruddin Pracha


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 April 2025 in Cancers
Verified
Journal Article
Open access
PDF file
MPMustaqueem Pallumeera
Mustaqueem Pallumeera
JGJonathan Chungheng Giang
Jonathan Chungheng Giang
RSRamanpreet Singh
Ramanpreet Singh
NPNooruddin Pracha
Nooruddin Pracha
MMMina S Makary
Mina S Makary
Artificial intelligence (AI) is revolutionizing cancer imaging, enhancing screening, diagnosis, and treatment options for clinicians. AI-driven applications, particularly deep learning and machine learning, excel in risk assessment, tumor detection, classification, and predictive treatment prognosis. Machine learning algorithms, especially deep learning frameworks, improve lesion characterization and automated segmentation, leading to enhanced radiomic feature extraction and delineation. Radiomics, which quantifies imaging features, offers personalized treatment response predictions across various imaging modalities. AI models also facilitate technological improvements in non-diagnostic tasks, such as image optimization and automated medical reporting. Despite advancements, challenges persist in integrating AI into healthcare, tracking accurate data, and ensuring patient privacy. Validation through clinician input and multi-institutional studies is essential for patient safety and model generalizability. This requires support from radiologists worldwide and consideration of complex regulatory processes. Future directions include elaborating on existing optimizations, integrating advanced AI techniques, improving patient-centric medicine, and expanding healthcare accessibility. AI can enhance cancer imaging, optimizing precision medicine and improving patient outcomes. Ongoing multidisciplinary collaboration between radiologists, oncologists, software developers, and regulatory bodies is crucial for AI’s growing role in clinical oncology. This review aims to provide an overview of the applications of AI in oncologic imaging while also discussing their limitations.

24 November 2024 in Cancers
Verified
Journal Article
Open access
PDF file
GWGavin Wu
Gavin Wu
NBNojan Bajestani
Nojan Bajestani
NPNooruddin Pracha
Nooruddin Pracha
CCCindy Chen
Cindy Chen
MMMina S Makary
Mina S Makary
Background/Objectives: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths globally, with prognosis and treatment outcomes that are significantly influenced by the stage at diagnosis. Early detection through regular surveillance is crucial for improving patient outcomes, especially in high-risk groups such as those with cirrhosis or chronic hepatitis B. Geographic variations in HCC risk factors, including viral hepatitis and non-alcoholic fatty liver disease (NAFLD), have led to the development of different international surveillance guidelines. This review aims to compare and evaluate the surveillance strategies proposed by the Asian Pacific Association for the Study of the Liver (APASL), the American Association for the Study of Liver Diseases (AASLD), and the European Association for the Study of the Liver and European Organization for Research and Treatment of Cancer (EASL–EORTC). Methods: The review examined and compared major international guidelines on HCC surveillance, focusing on patient selection, imaging modalities, and the integration of biomarkers. We also explored recent advancements in screening techniques, including artificial intelligence and emerging biomarkers, to identify future directions for improving surveillance strategies. Results: Our analysis identified key differences in the guidelines, particularly in imaging modality preferences and the use of biomarkers for early detection. While all guidelines place emphasis on high-risk populations, the inclusion criteria and surveillance intervals vary. Additionally, novel technologies such as artificial intelligence show potential to enhance the accuracy and efficiency of HCC detection. Conclusions: This review highlights the need to harmonize the international guidelines, particularly in regard to patients with non-cirrhotic NAFLD who remain under-represented in current surveillance protocols. Future research should focus on integrating emerging technologies and biomarkers to improve early detection and overall patient outcomes.

5 April 2023 in Cells
Verified
Journal Article
Open access
PDF file
DSDivya Sridharan
Divya Sridharan
NPNooruddin Pracha
Nooruddin Pracha
SRSchaza Javed Rana
Schaza Javed Rana
SASalmman Ahmed
Salmman Ahmed
ADAnam Dewani
Anam Dewani
Mahmood KhanMahmood Khan
Mahmood Khan
Myocardial Infarction (MI) occurs due to a blockage in the coronary artery resulting in ischemia and necrosis of cardiomyocytes in the left ventricular heart muscle. The dying cardiac tissue is replaced with fibrous scar tissue, causing a decrease in myocardial contractility and thus affecting the functional capacity of the myocardium. Treatments, such as stent placements, cardiac bypasses, or transplants are beneficial but with many limitations, and may decrease the overall life expectancy due to related complications. In recent years, with the advent of human induced pluripotent stem cells (hiPSCs), newer avenues using cell-based approaches for the treatment of MI have emerged as a potential for cardiac regeneration. While hiPSCs and their derived differentiated cells are promising candidates, their translatability for clinical applications has been hindered due to poor preclinical reproducibility. Various preclinical animal models for MI, ranging from mice to non-human primates, have been adopted in cardiovascular research to mimic MI in humans. Therefore, a comprehensive literature review was essential to elucidate the factors affecting the reproducibility and translatability of large animal models. In this review article, we have discussed different animal models available for studying stem-cell transplantation in cardiovascular applications, mainly focusing on the highly translatable porcine MI model.

25 February 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
EPEmily L. Pfahl
Emily L. Pfahl
NPNooruddin Pracha
Nooruddin Pracha
MEMohamed H. Emlemdi
Mohamed H. Emlemdi
PLPhuoc-Hanh Le
Phuoc-Hanh Le
MMMina S Makary
Mina S Makary
The integration of artificial intelligence (AI) into medicine, oncology, and radiology represents a marked shift in the diagnosis, prognostication, and management of hepatocellular carcinoma (HCC), a malignancy with high global incidence and poor prognosis. This review examines the application of AI, including machine learning (ML) and deep learning (DL), across the spectrum of HCC care. As AI advances, new convolutional neural networks (CNNs) and other models are enhancing diagnostic accuracy, reducing interpretation times, and improving the characterization of liver lesions across major imaging modalities including ultrasound, computed tomography (CT), and magnetic resonance imaging (MRI). Beyond diagnosis, the transformative role of AI in prognostication is also improving, where AI can now noninvasively predict critical factors such as microvascular invasion, genetic mutation status, tumor recurrence, and treatment response. Furthermore, AI has shown promise in facilitating patient-specific treatment planning by stratifying patients for interventions such as transarterial chemoembolization (TACE) and stereotactic body radiation therapy (SBRT). The review also addresses the emerging fields of pathomics and the use of AI in positron emission tomography (PET), while critically evaluating the cost-effectiveness of these technologies. Despite its promise, the widespread clinical adoption of AI faces challenges, including limited generalizability, maintaining patient privacy, ethical considerations, and the need for robust prospective validation. Ultimately, this review illustrates that the future of HCC management lies in a collaborative, hybrid-intelligence model, where AI-driven insights augment clinical expertise to optimize diagnostic pathways, personalize therapy, and improve patient outcomes.

19 June 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
SASyed Baseeruddin Alvi
Syed Baseeruddin Alvi
NPNooruddin Pracha
Nooruddin Pracha
MSMahmoud Shalaan
Mahmoud Shalaan
PDPankaj Singh Dholaniya
Pankaj Singh Dholaniya
MMMuhamad Mergaye
Muhamad Mergaye
Mahmood KhanMahmood Khan
Mahmood Khan
Heart disease is one of the leading causes of death in the United States and throughout the world. While there are different techniques for reducing or preventing the impact of heart disease, nitric oxide (NO) is administered as nitroglycerin for reversing angina or chest pain. Unfortunately, due to its gaseous and short-lived half-life, NO can be difficult to study or even administer. Therefore, controlled delivery of NO is desirable for therapeutic use. In the current study, the goal was to fabricate NO-releasing microspheres (MSs) using a donor molecule, S-Nitroso-N-Acetyl penicillamine, (SNAP), and encapsulating it in poly(ε-caprolactone) (PCL) using a single-emulsion technique that can provide sustained delivery of NO to cells over time without posing any toxicity risks. Optimization of the fabrication process was performed by varying the duration of homogenization (5, 10, and 20 min) and its effect on entrapment efficiency and size. The optimized SNAP-MS had an entrapment efficiency of ˃50%. Furthermore, we developed a modified method for NO detection by using NO microsensors to detect the NO release from SNAP-MSs in real time, showing sustained release behavior. The fabricated SNAP-MSs were tested for biocompatibility with HUVECs (human umbilical vein endothelial cells), which were found to be biocompatible. Lastly, we tested the effect of controlled NO delivery to human induced pluripotent stem-derived cardiomyocytes (hiPSC-CMs) via SNAP-MSs, which showed a significant improvement in the electrophysiological parameters and alleviated anoxic stress.